EnsoData, Inc. announced that it has received $20 million in funding from a group of investors
May 11, 2022
Share
On May 12, 2022, EnsoData, Inc. closed the transaction. On the same date the company received $10,000,000 in its second tranche closing, bringing the total gross proceeds raised in the transaction to $20,000,000. The tranche was led by new investor, Inspire Medical Systems, Inc. with participation from existing investors including Zetta Venture Partners, Venture Investors, LLC, Supermoon Capital, Colle Capital Partners LP, HealthX Ventures, M25 Group, Board members Justin Mortara, ??Fred Robertson, MD, and other investors. The company received $19,999,975 pursuant to exemption provided under Regulation D from 11 investors.
Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire system is the FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The Company has developed a novel, closed-loop solution that continuously monitors a patientâs breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sell its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ENT physicians and sleep centers.